GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TalkMed Group Ltd (SGX:5G3) » Definitions » GF Value

TalkMed Group (SGX:5G3) GF Value : S$0.55 (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is TalkMed Group GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-27), TalkMed Group's share price is S$0.415. TalkMed Group's GF Value is S$0.55. Therefore, TalkMed Group's Price-to-GF-Value for today is 0.75.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes TalkMed Group is Modestly Undervalued.


TalkMed Group  (SGX:5G3) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

TalkMed Group's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=0.415/0.55
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TalkMed Group GF Value Related Terms

Thank you for viewing the detailed overview of TalkMed Group's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


TalkMed Group (SGX:5G3) Business Description

Traded in Other Exchanges
N/A
Address
3 Mount Elizabeth, Mount Elizabeth Hospital Level 2, Singapore, SGP, 228510
TalkMed Group Ltd operates as an investment holding company. It is a provider of medical oncology, stem cell transplants and palliative care services, serving patients in Singapore and the region. Outside Singapore, the Group operates in Vietnam, Hong Kong and the People's Republic of China. The activities of the company are the provision of medical oncology services and palliative care healthcare services in Singapore. It is organized into three reportable operating segments, Oncology Services, Stem Cells Services and Cellular and gene therapy-related products and services. The company has operational footprints across Singapore, Hong Kong and Vietnam of which Singapore contributes the vast majority of total revenue. It generates maximum revenue from the Oncology services segment.

TalkMed Group (SGX:5G3) Headlines

No Headlines